Hims & Hers drops plan for knockoff of Novo Nordisk's new Wegovy weight loss pill

Telehealth company abandons plan to offer unapproved compounded version of popular weight-loss medication after FDA warning.

Published on Feb. 7, 2026

Got story updates? Submit your updates here. ›

Telehealth company Hims & Hers has dropped its plan to offer a compounded version of the new weight-loss pill Wegovy, just two days after announcing the new drug. The decision came after Novo Nordisk, the maker of Wegovy, threatened to sue Hims, and the FDA said it plans to limit access to the active ingredients in popular GLP-1 weight-loss drugs like Wegovy.

Why it matters

This case highlights the ongoing tensions between telehealth companies offering cheaper alternative medications and pharmaceutical giants protecting their approved and patented drugs. It also raises questions about the FDA's role in regulating compounded medications, especially for in-demand weight-loss treatments.

The details

Hims had planned to significantly undercut Novo's $149 per month price for Wegovy by selling its compounded version for $49 the first month and $99 per month thereafter. However, the compounded medicine Hims planned to sell was not FDA-approved and had not gone through clinical trials to demonstrate effectiveness. After Novo threatened legal action and the FDA said it would limit access to GLP-1 drug ingredients, Hims announced it would no longer offer the compounded semaglutide pill.

  • On February 5, 2026, Hims announced it would offer a compounded version of the new Wegovy weight-loss pill.
  • On February 6, 2026, Novo Nordisk threatened to sue Hims over the plan.
  • On February 6, 2026, the FDA said it plans to take steps to limit access to the active ingredients in popular GLP-1 weight-loss drugs like Wegovy.
  • On February 7, 2026, Hims announced it would stop offering the compounded semaglutide pill.

The players

Hims & Hers

A telehealth company that had planned to offer a compounded version of the new Wegovy weight-loss pill at a lower price than the original.

Novo Nordisk

The Danish pharmaceutical company that manufactures the new FDA-approved Wegovy weight-loss medication.

U.S. Food and Drug Administration (FDA)

The federal agency that regulates the approval and distribution of drugs in the United States, and which announced plans to limit access to the active ingredients in popular GLP-1 weight-loss medications.

Got photos? Submit your photos here. ›

What they’re saying

“'Since launching the compounded semaglutide pill on our platform, we've had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment.'”

— Hims & Hers (X)

What’s next

Novo Nordisk is expected to heavily promote its new FDA-approved Wegovy weight-loss pill with a celebrity-filled Super Bowl ad on Sunday. Rival drugmaker Eli Lilly also plans to seek FDA approval for an oral version of its own weight-loss medication, orforglipron, later this spring.

The takeaway

This case highlights the ongoing tensions between telehealth companies seeking to offer cheaper alternative medications and pharmaceutical giants protecting their approved and patented drugs. It also raises questions about the FDA's role in regulating compounded medications, especially for in-demand treatments like weight-loss drugs.